Scilex Holding (SCLX) Intangibles (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Intangibles of $59.8 million for Q1 2026, down 1.6% year-over-year from $60.8 million in Q1 2025, and down 34.84% on a QoQ basis from $91.8 million in Q4 2025.
Scilex Holding (SCLX) Intangibles (2021 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Intangibles for 6 consecutive years, with $59.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Intangibles fell 1.6% year-over-year to $59.8 million; the TTM figure through Mar 2026 stood at $59.8 million (down 1.6% YoY), while the FY2025 annual figure was $91.8 million, up 51.0% from the prior year.
- Intangibles came in at $59.8 million for Q1 2026 at Scilex Holding, down from $91.8 million in the prior quarter.
- The five-year high for Intangibles was $91.8 million in Q4 2025, with the low at $5.0 million in Q1 2022.
- Average Intangibles over 5 years is $42.2 million, with a median of $38.5 million recorded in 2023.
- Across the five-year window, Intangibles surged 1115.62% in 2023 and slumped 48.27% in 2025, its largest moves.
- Year by year, Intangibles stood at $40.6 million in 2022, then soared by 49.74% to $60.8 million in 2023, then changed by 0.0% to $60.8 million in 2024, then surged by 51.0% to $91.8 million in 2025, then slumped by 34.84% to $59.8 million in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $59.8 million, $91.8 million, and $30.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.37 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 49.06 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 50.87 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 36.91 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 25.75 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 21.38 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 16.38 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 52.56 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 11.30 Bn |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 59.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.81 Mn |
| Dec 31, 2025 | 91.78 Mn |
| Sep 30, 2025 | 30.42 Mn |
| Jun 30, 2025 | 31.44 Mn |
| Mar 31, 2025 | 60.78 Mn |
| Dec 31, 2024 | 60.78 Mn |
| Sep 30, 2024 | 33.45 Mn |
| Jun 30, 2024 | 60.78 Mn |
| Mar 31, 2024 | 35.46 Mn |
| Dec 31, 2023 | 60.78 Mn |
| Sep 30, 2023 | 37.51 Mn |
| Jun 30, 2023 | 38.54 Mn |
| Mar 31, 2023 | 60.78 Mn |
| Dec 31, 2022 | 40.59 Mn |
| Sep 30, 2022 | 5.00 Mn |
| Jun 30, 2022 | 5.00 Mn |
| Mar 31, 2022 | 5.00 Mn |
| Dec 31, 2021 | 38.80 Mn |